
    
      The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to
      treat people who have active UC or CD.

      The study will enroll approximately 150 patients. Participants will be assigned to the
      vedolizumab treatment group.

      â€¢Vedolizumab 300 mg

      Vedolizumab 300 mg IV infusion will be administered once in Weeks 0, 2, 6 and 10
      (CD-participants who have not shown a response can receive a dose at Week 10) during
      induction phase and in Weeks 14, 22, 30, 38 and 46 during maintenance phase.

      This multicentre trial will be conducted in India. The overall time to participate in this
      study is 74 weeks. Participants will make multiple visits to the clinic, and will be
      contacted by telephone plus a final visit after receiving their last dose of drug for a
      follow-up assessment.
    
  